Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune disease LISRAYA is a once-daily pill that directly targets key immune pathways implicated in dermatomyositis pathogenesis LISRAYA demonstrated robust